The panel interrogated > 1800 cancer-associated mutations within AKT1, ALK, BRAF, CTNNB1, DDR2, EGFR, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, KRAS, NRAS, MAP2K1, MET, NOTCH1, PIK3CA, PTEN, SMAD4, STK11 and TP53. In short, we found no cancer-related mutations using this panel, nor did we find any evidence of a TERT promoter mutation as analyzed by conventional Sanger sequencing. Here, MET is linked to cancer.